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ABSTRACT 
The design of the present investigation was to prepare Losartan bounded pharmacosomes 
to improve the water solubility, bioavailability and minimize the toxicity of Losartan. 
Pharmacosomes is a potential approaches in vesicular drug system which exhibits several 
advantages over conventional vesicular drug delivery systems. Pharmacosomes are 
phosphilipid complexes with a potential to improve bioavailability of poorly water soluble 
as well as poorly lipophilic drugs. Losartan was complexed with soya phosphatidylcholine 
in various ratio using conventional solvent evaporation technique. Pharmacosomes thus 
prepared were subjected to drug solubility, drug content evaluation, surface morphology 
(by scanning electron microscopy), crystallinity (by x-ray powder diffraction), quality 
control tests for capsules and in-vitro dissolution study. Solubility profile of the prepared 
complex was found to be much better than Losartan pure drug. The improvement in 
solubility of the prepared pharmacosomes may be result in improved dissolution and lower 
gastrointestinal toxicity. Drug content was found to be 96.83% w/w for the optimized 
Losartan phospholipid complex F1 (Losartan: lecithin ratio of 1:1). The pharmacosomes 
were found to be disc shaped in scanning electron microscopy. X-ray powder diffraction 
data confirmed the formulation of phospholipid complex. The formulation F1 showed 
94.69% drug release while the free Losartan showed data of only 60.42% at the end of 10 
hours dissolution study. Thus the solubility and hence the bioavailability of Losartan can 
be increased to a greater extend by complexing it with soya phosphatidylcholine. 
Key words: Losartan, Bioavailability, pharmacosomes, phospholipid complex, solubility.    
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PHARMACOSOMES 
       Pharmacosomes bear unique advantages over liposome and noisome vesicles and 
serve as an alternative to conventional vesicles. They are the colloidal dispersions of drugs 
covalently bound to lipids. Depending upon the chemical structure of the drug-lipid 
complex they may exist as ultrafine vesicular, micellar, or hexagonal aggregates. As the 
system is formed by linking a drug (pharmakon) to a carrier (soma), they are termed as 
“pharmacosomes”. They serve as an effective tool to achieve desire therapeutic goals in 
terms of drug targeting and controlled release of drug. The criterion for the development 
of the vesicular pharmacosome is dependent on surface and bulk interactions of lipids.8 
        Any drug possessing an active hydrogen atom can be esterified into the lipid, with or 
without spacer chain that strongly result in the formation of an amphiphilic compound, 
which facilitates better penetration in to the target site. The prodrug conjoins with 
hydrophilic and lipophilic properties, thus acquires amphiphilic characters. The 
amphiphilic characters help pharmacosomes to reduce the interfacial tension and at higher 
contraction exhibits mesomorphic behavior. This decrease in the interfacial tension leads 
to an increase in the contact area, thereby increasing the bioavailability of drug.9 
       The phospholipids, when placed in water form micelles or are organized as lipid 
bilayers with the hydrophobic tails lined up against one another and the hydrophilic head-
group facing the water on both sides. These unique features make phospholipids most 
suitable to be used as excipients for poorly water soluble drugs. Thus, the enhanced 
solubility of lipophilic drugs from lipid-based systems will not necessarily arise directly 
from the administered lipid, but most likely from the intra-luminal processing to which it 
is subjected before it get absorbed.10 
       The pharmacosomal drug delivery system is advancing as a method used for delivery 
of various drug like non-steroidal anti-inflammatory drugs (NSAIDs), cardiovascular 
drugs, antineoplastic drugs and proteins. A drug possessing a free carboxyl group or an 
active hydrogen atom can be esterified to the hydroxyl group of a lipid molecule, thereby 
producing an amphiphilic pordrug. Phosphatidylcholine (PC) complex of non-steroidal 
anti-inflammatory drugs (NSAIDs) improve the permeation of these drugs across the 
biomembranes and thereby improving their bioavailability to target sites. GI safety of 
NSAIDs has been reported to be improved upon complexation or any other interaction 
Introduction 
 
Dept of Pharmaceutics,KMCH College of Pharmacy                                                      2 
with phospholipid. The phospholipid (acting as surfactant) provide a protective 
hydrophobic cover on the surface of the mucus to protect the GI tissue.8 
ADVANTAGE OF PHARMACOSOMES9 
1. As the drug is covalently bound to lipid, membrane fluidity has no effect on release 
rate, but depends upon the phase-transition temperature of the drug-lipid complex. 
2. No leaching of drug takes place because the drug is covalently bound to the carrier. 
3. Drugs can be delivered directly to the site of infection. 
4. Drug release from pharmacosomes is generally governed by hydrolysis (including 
enzymatic). 
5. Their degradation velocity into active drug molecule, after absorption depends on 
their size and functional groups of the drug molecules, the chain length of the 
lipids, and spacer. 
6. Reduced cost of therapy 
7. Suitable for both hydrophilic and lipophilic drugs. The aqueous solution of these 
amphiphiles exhibits concentration dependant aggregation. 
8. High and predetermined entrapment efficiency as the drug and the carrier are 
covalently linked together. 
9. Volume of inclusion does not influence the entrapment efficiency. 
10. No need of removing the free un-entrapped drug from the formulation which is 
required in case of liposomes. 
11. Improves bioavailability especially in case of poorly soluble drugs. 
12. Reduction in adverse effect and toxicity. 
 
ADVANTAGES OF PHARMACOSOMES OVER CONVENTIONAL 
VESICULAR SYSTEM10 
1. In case of pharmacosomes, volume of inclusion does not influence the 
entrapment efficiency. On the other hand, in case of lipsomes, the volume of 
inclusion has great influence on entrapment efficiency. 
2. In pharmacosomes, the membrane fluidity depends upon the phase transition 
temperature of drug-lipid complex but it has no effect on release rate because 
the drug-lipid composition is one of the crucial factors that decided its 
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membrane fluidity, which affect the rate of drug release and physical stability 
of the system. 
3. Drug release from pharmacosomes is by hydrolysis (including enzymatic) 
unlike lipsomes the release of drug is by diffusion through bilayer, desorption 
from the surface of degradation of lipsomes. 
4. Unlike lipsomes in pharmacosomes there is no need of following the tedious, 
time consuming step for removing the free, un-entrapped drug from the 
formulation. 
5. In liposomes there are chance of sedimentation and leaching of drug, but in 
pharmacosomes the incident of leakage of drug does not take place because the 
drug is covalently linked to the carrier. 
SALIENT FEATURES OF PHARMACOSOMES 11 
1.  Entrapment efficiency is not only high but predetermined, because drug itself in 
conjugation with lipids from vesicles. 
2. There is no need of following the tedious, time-consuming step for removing the 
free, un-entrapped drug from the formulation. 
3. Since the drug is covalently linked, loss due to leakage of drug, does not take 
place. However, loss may occur by hydrolysis. 
4. No problem of drug incorporation into the lipids. 
5. In pharmocosome, the encaptured volume and drug-bilayer intractions do not 
influence the entrapment efficiency. 
6. In case of pharmacosomes, the membrane fluidity depends upon the phase 
transcition temperature of the drug lipid complex, but it does not affect release rate 
since the drug is covalently bound to lipids. 
7. Phospholipid transfer/exchange is reduced, and solubilization by HDL is low. 
8. The physicochemical stability of the pharmacosomes depends upon the 
physicochemical properties of the drug-lipid complex. 
9. Following absorption, their degradation velocity into active drug molecule depends 
to great extent on the size and functional groups of drug molecule, the chain length 
of the lipids, and the spacer. These can be varied relatively precisely for optimized 
in vivo pharmacokinetics. 
10. They can be given orally, topically, extra or intra vascularly. 
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LIMITATION11 
1. Synthesis of a compound depends upon its amphiphilic nature. 
2. It requires surface and bulk intraction of a lipid with drugs.  
3. It requires covalent bonding to protect the leakage of drugs. 
4. Pharmacosomes, on storage, undergo fusion and aggregation, as well as chemical 
hydrolysis. 
COMPONENTS USED FOR THE FORMULATION OF PHARMACOSOMES 
 
There are three essential components for pharmacosomes preparation. 
 
Drugs 
 
 Drugs containing active hydrogen atom (-COOH, OH, NH2) can be esterified to 
the lipid, with or without spacer chain and they form amphiphilic complex which in 
turn facilitate membrane, tissue, cell wall transfer in the organisms. 
 
 Solvents 
 
           For the preparation of pharmacosomes, the solvents should have high purity and 
volatile in nature. A solvent with intermediate polarity is selected for pharmacosomes 
preparation. 
 
Lipids 
 
       Phospholipids are the major structure component of biological membranes, where two 
types of phospholipids such as phosphoglycerides and sphingolipids are generally used. 
The most common phospholipid is phosphotidyl choline moiety. Phosphotidyl choline is 
an amphiphilic molecule in which a glycerol bridges links a pair of hydrophobic acyl 
hydrocarbon chains, with a hydrophilic polar head group phosphocholine. Most 
commercial lecithin products contain 20% phosphatidylcholine. Lecithins containing 
phosphatidylcholine can be obtained from vegetables (mainly), animals and microbial 
sources. Lecithin is also available as a dietary supplement in two forms: as granular 
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lecithin (oil-free refined lecithin with calcium phosphate as a flow agent); and as capsules 
containing a dispersion in oil. 
 
FORMULATION OF PHARMACOSOMES7, 12 
 
      There are various methods which have been employed to prepare vesicles; 
   
1. Solvent evaporation method 
 
       In the solvent evaporation method of preparing the pharmacosomes, the drug is 
first acidified so that the active hydrogen might be available for complexation. The drug 
acid is then extracted into chloroform and subsequently recrystallized. The drug-PC 
complex is prepared by associating drug acid with PC in various molar ratios. The 
accurately weighed PC and drug acid are placed in a 100 ml round bottom flask and 
dissolved in sufficient amount of dichloromethane. The mixture is refluxed for one hour. 
Then the solvent is evaporated off under vacuum at 40 ° C in a rotary vacuum evaporator. 
The dried residues are then collected and placed in vacuum dessicator for complete drying. 
         
2. Hand –shaking method 
 
   In the hand-shaking method, a mixture of drug and lipids are dissolved in 
volatile organic solvent such as dichloromethane in a round bottom flask. The organic 
solvent is removed at room temperature using a rotary vaccum evaporator, which 
leaves a thin film of solid mixture deposited on walls of flask. The dried film can then 
be hydrated with aqueous media and gives a vesicular suspension.  
 
3. Ether injection method 
 
          In this method solution containing drug-lipid complex is slowly injected 
into a hot aqueous medium through gauze needle and vesicle is formed readily. 
 
4. Anhydrous co-solvent lyophilisation method 
Drug powder and phospholipids dissolved in 1ml of Dimethylsulfoxide 
(DMSO) containing 5% glacial acetic acid, after that agitates the mixture to get 
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clear liquid. Freeze –dried overnight at condenser temperature .Then resultant 
complex flushed with nitrogen & Stored at 4°C.    
 
5. Supercritical fluid process  
              This method is known as solution enhanced dispersion by complex supercritical 
fluid. Drug and lipid complex are premixed in a supercritical fluid of carbondioxide, then 
high supersaturation is obtained by passing through the nozzle mixture chamber.The 
turbulent flow of solvent and carbondioxide results in fast mixing of dispersion leading to 
the formation of pharmacosomes.    
  6. Alternative Approach 
An alternative approach for producing pharmacosomes is to synthesize a 
biodegradable micelle-forming drug conjunct from the hydrophobic drug adriamycin and a 
polymer composed of polyxyethylene glycol and polyaspartic acid. This approach 
provides an advantage that all though micelle can be diluted, the drugs probably not 
precipitate due to the water solubility of the monomeric drug conjuncts. 
CHARACTERIZATION OF PHARAMACOSOMES 5, 6 
 
1) FTIR spectroscopy 
  
   The formation of the complex can be confirmed by IR spectroscopy comparing the 
spectrum of the complex with the spectrum of individual components and their mechanical 
mixture. Stability of pharmacosomes can be evaluated by comparing the spectrum of the 
complex in solid form with the spectrum of its micro dispersion in water after 
lyophilization, at different time intervals. 
 
2) Surface Morphology 
  Surface morphology of the pharmacosomes can be observed with scanning 
electron microscopy (SEM) or transmission electron microscopy (TEM). The shape and 
size of the pharmacosomes may be affected by the purity grades of phospholipid and the 
process variables such as speed of rotation, vacuum applied or the method used. 
Pharmacosomes prepared by low purity grades of lipids yields a greasy product, which in 
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turn results in the formation of sticky large aggregates. Pharmacosomes prepared by very 
high purity grades (>90%) lipids are prone to oxidative degradation, which in turn 
adversely affect the stability of complexes. Most commonly used phospholipids are of 
80% purity. 
3) Solubility Studies 
 
   Solubility of the drug, phospholipids, their physical mixture and the 
pharmacosomes can be determined by the shake-flask method where two phases are 
mutually saturated before use. Equal volume of buffer solution with a different pH(from 
2.0 to 7.4) and 1-octanol containing phospholipid complex are mixed properly in the screw 
capped penicillin bottles and equilibrated under constant shaking at 37°c for 24 hours. 
After separating the aqueous phase, the concentration of drug in this aqueous phase is 
determined by HPLC or UV spectrophotometer. 
 
4)  X-ray powder diffraction.  
It has been performed to determine the degree of crystallinity by using the relative 
integrated intensity of reflection peaks. The integrated intensity is given by the area under 
curves of the XRPD patterns and it represents the specimen characteristics. 
 
5) In-vivo and In-vitro evaluation 
Depending upon the expected therapeutic activity of biologically active constituents, 
models of in-vivo and in-vitro evaluations are carried out. In-vitro dissolution studies can 
be done with media of different pH in a standard dissolution apparatus to determine the pH 
in a standard dissolution apparatus to determine the pH dependent dissolution profile. 
 
APPLICATIONS OF PHARMACOSOMES 9, 11 
1. Pharmacosomes demonstrate a wider stability profile and greater shelf life. 
2. Pharmacosomes have the capacity to augment drug absorption and its transport. 
3. Pharmacosomes can improve the rate of permeation by improving the membrane 
fluidity. The transition temperature of vesicles in the form of vesicles and micelles 
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might pose an evident effect on vesicular interaction with biomembrane, hence 
improving the transfer of drug across membrane. 
4. Pharmacosomes have achieved a new level by enhancing therapeutic effects of 
several drugs like pindolol derivative, toxol, bupronolol acid derivative, cytarabin, 
amoxicillin, etc. 
5. Pharmacosomes, the amphiphilic lipid vesicular system, can be used for the 
development of novel ophthalmic dosage forms. Amphiphilic prodrug forms 
pharmacosomes, when diluted with tear, and modify corneal drug transport and 
release profile. 
6. Pharmacosomes have greater degree of selectivity for action on specific target 
cells. 
 
 
 The oral route of drug administration is the most important route of administering 
drugs for systemtic effect. About 90% of drug is used to produce systemic effect are 
administered by oral route. When a new drug is discovered one of the first questions a 
pharmaceuticst asks is whether or not the drug can be effectivelyadministered for its 
intended effect by the oral route. 
 The drug that are administerted orally,solid oral dosage formrepresent the preferred 
class of products. The reasons for this preference are as follows. Capsule is unit dosage 
form in which one usual dose of the drug has been accurately  filled in the capsules. 
Liquid dosage forms, such as syrups, suspensions, emulsions, solutions and elixirs are 
usually designed to contain and dose of medication in 5 to 30 ml and the patient is then 
asked to measure his or her own medication using teaspoons, tablespoon or other device. 
Such dosage measurements are typically in error by a factor ranging from 20 to 50% when 
the drug is self administered by the patients. 
  
LOSARTAN 
Losartan is the potassium salt form of losartan, a non-peptide angiotension II 
antagonist with antihypertensive activity. Angiotensin II, formed from angiotensin I by 
angiotensin-converting enzyme (ACE), stimulates the adrenal cortex to synthesize and 
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secret aldosterone, which decrease the excretion of sodium and increase of potassium. 
Angiotension II also acts as a vasoconstrictor in vascular smooth muscle. 
  Losartan is an angiotension II receptor antagonist drug used mainly to treat high 
blood pressure. It is well absorbed oral administration and undergoes significant first-pass 
metabolism. It may also delay progression of diabetic nephropathy and is associated with a 
positive clinical outcome in that regard. Lowering high blood pressure helps prevent 
strokes, heart attacks, and kidney problems. It works by relaxing blood vessels so the 
blood can flow more easily. It is freely soluble in water and sparingly soluble in ethyl 
acetate, butyl acetate and cyclohexane, and the solubility in these three solvents varys little 
with the temperature, which affect it’s dissolution in GI fluid and leads to poor 
bioavailability. The diffusion of drug across lipid membranes and into target cells is 
accelerated when they are in a complex with phosphatidylcholine. 
  Based on the above observation, it was concluded to formulate pharmacosomes for 
the oral delivery of Losartan and evaluated for the improvement in solubility, drug loading 
and drug release. Findings of the research are included in this thesis. 
  
Review of literature 
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                                          REVIEW OF LITERATURE 
 
1.Ajay semalty et al (2010)., 20 Developed and evaluated pharmacosomes of acelofenac. 
The pharmacosomes was prepared to recover the water solubility, bioavailability and 
minimize the gastrointestinal toxicity of acelofenac. Acelofenac was complexed with 
phosphatidylcholine (80%) in two different ratios (1:1 and 1:2) by the conventional 
solvent evaporation technique. Pharmacosomes thus prepared were subjected to solubility 
and content evaluation, SME, XRD, DSC and in-vitro dissolution study. Drug content was 
found to be 91. 88% (w/w) for acelofenac phospholipid complex (1:1) and 89.03 %( w /w) 
aceclofenac-phospholipid complexes (2:1). The datas obtained from DSC thermograms 
and XRD confirmed the formation of phospholipid complex. Solubility and dissolution 
summary of the pharmacosomes was found to be much better than aceclofenac. 
 
2.Savita patil et al (2014).,21 Investigated the in-vitro and ex-vivo classification of 
furosemide bounded pharmacosomes thus improving the solubility and permeability of the 
drug. The furosemide pharmacosomes were prepared by simple solvent evaporation 
technique. Furosemide bounded pharmacosomes formulation (PMC1 & PMC2) were 
prepared and compared with pure drug which showed a fivefold increase in the solubility 
and a significant increase in permeability of furosemide bounded pharmacosomes. In-vitro 
release profile exhibits excellent sustained drug release properties. Prepared furosemide 
bounded pharmacosomes were confirmed by using differential scanning calorimetry 
(DSC), X-ray diffraction (XRD) and FT-IR. 
 
3.Harikumar et al (2010)., 22 To recover the water solubility, bioavailability and diminish 
the gastrointestinal toxicity of ketoprofen, its pharmacosomes were planned and 
developed. Ketoprofen was complexed with phosphatidylcholine in various ratios with 
conventional solvent evaporation method. Pharmacosomes thus prepared were subjected 
to solubility and drug content evaluation, scanning electron microscopy, differential 
scanning calorimetry, X ray powder diffraction, in-vitro dissolution and in-vitro diffusion 
Review of literature 
 
Dept of Pharmaceutics, KMCH College of Pharmacy                                                                 11 
study. Pharmacosomes of ketoprofen were found to be disc shaped with rough surface in 
SME. Solubility and in-vitro dissolution profile of pharmacosomes was found to be 99.8% 
and showed high percentage of drug loading.DSC thermograms and  X ray powder 
diffraction datas confirmed the formation of phospholipid complex. In-vitro diffusion rate 
of ketoprofen from pharmacosomes was significantly higher. The release experiments 
clearly indicated sustained release of ketoprofen from pharmacosomal formulation.     
 
4.Han M et al (2010).,23  The 20(S)-photopanaxadiol (Ppd) pharmacosomes was 
successfully prepared by thin film dispersion and its in-vitro stability was studied. The 
particle size of pharmacosomes was evaluated by dynamic scattering (DLS) and the 
encapsulation efficiency of ppd pharmacosomes was 80.84±0.53% with a diameter of 
100.1nm. in addition, the effect of some factors on the encapsulation efficiency and the 
particle size such as temperature, alcohol, pH and artificial gastro-intestinal fluids, were 
also investigated. The selected formulation and technology were simple and practical to 
prepare ppd pharmacosome. 
 
5.Ajay semalty et al (2009)., 24 To improve the water solubility of diclofenac, and also to 
decrease its gastrointestinal toxicity, the pharmacosomes containing diclofenac were 
prepared and evaluated for physicochemical analysis. Diclofenac was complexed with 
phosphatidylcholine (80%) in equimolar ratio, in the presence of the organic solvent 
dichloromethane, by the conventional solvent evaporation technique. Pharmacosomes thus 
prepared were evaluated for drug solubility, drug content, surface morphology, phase 
transition behavior, crystallinity and in-vitro dissolution. Pharmacosomes of diclofenac 
were found to be irregular or disc shaped with rough surface in SEM. Drug content was 
found to be 96.2±1.1%. DSC thermograms and XRPD data confirmed the formation of the 
phospholipid complex. Water solubility of the prepared complex was found to be twice 
than that of the pure drug. The improvement in water solubility of prepared 
pharmacosomes resulted in improved dissolution and lower gastrointestinal toxicity. 
Pharmacosomes showed 87.8% while the free diclofenac acid showed a total of only 
60.4% drug release at the end of 10 hour dissolution study. 
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6.Patel R A et al (2010)., 25 The pharmacosomes containing the β-blockers bupranolol 
were designed and developed. The pharmacosomes was then covalently linked to 1, 3-
dipalmioyl-2-succinyl-glycerol. The resulting prodrug was   amphipathic and dispersed 
readily in water above 30°c forming a smectic lamellar phase. The dispersion, similar to 
charged phospholipids showed continuous swelling with increasing water content and so 
in excess water region, the thermodynamically most stable structure was the unilamellar 
vesicles which oligomeric vesicles were also formed. Enhanced effect on intraocular 
pressure in rabbit was observed after incorporation in pharmacosomes. 
 
7.Chauhan N et al (2009)., 26 Synthesized various amphipathic liponucletide 
pharmacosomes, 1-β-D-arabinofuranosylcytosine 5’-diacylglycerols (containing either 
dimyistoyl distearoyl free fatty acid side chain) and determined the aggregation and 
morphological characteristics of their sonicated dispersion in relation to change in 
temperature. The sonication at low temperature gave turbid solutions containing layer 
bilayer sheets. On raising the temperature, atrastion temperature (tg) was reached at which 
a stable three dimensional cross-linked network of small interlocking bilayer stacks was 
formed. Sonication at the temperature close to tg produced small disc-shaped micellar 
structures. These micelles were shown to exist another aggregational equilibrium 
consisting of stacking –destacking process. In this study the biological activity was found 
to be improved after incorporation of drugs (taxol and cytarabin) into pharmacosomes. 
 
8.Vaizoglu et al (2009)., 27 synthesized phospholipid complexes of the drug pindolol via 
spacer (succinic acid). This prodrug having structural similarity with lysolecithin reduced 
the interfacial tension between benzene/water and opalescent vesicular dispersion could be 
obtained by the film method and ether injection method .It was combined with tween-80 
and pharmacosomes were prepared by the film method. The in-vitro fate was studied in 
beagle dogs by administering the pharmacosomes and parent drug through oral and 
intravenous route and determining the plasma concentrations of unchanged pindolol. 
Plasma drug profile followed the one compartment open compartment open model, 
indicating rapid hydrolysis in body fluids. Three to five times higher concentrations of 
unchanged pindolo were observed following intravenous administration of the 
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pharmacosomes rather than free pindolol. Urine data indicating lowering of renal 
clearance when administered as pharmacosomes. 
 
9.Peng yue et al (2012)., 28 Prepared and characterized geniposide-pharmacosomes 
(GPPMS) and optimized the process and formulation variables using response 
methodology. Tetrahydrofuran was used as a reaction medium, geniposide and 
phospholipids were resolved into the medium, and GP-PMS was formed after the organic 
solvent was evaporated off under vacuum condition. The process and formulation 
variables were optimized by central composite design (CCD) of response surface 
methodology (RSM). The phospholipid-to-drug ratio (X1), reaction temperature (X2) and 
the drug concentration (X3) were selected as independent variables and the yield (%) of 
GP ‘present as a complex’ in the PMS was used as the dependent variable. The physico-
chemical properties of the complex obtained by optimal parameters were investigated by 
means of FT-IR, differential scanning calorimetry, n-octanol /Water partition coefficient 
(P) and particle size analysis. Multiple linear regression analysis for optimization by CCD 
revealed than the higher yield of GP ‘present as a complex’ in the GP-PMS was obtained 
wherein the optimal setting of XI, X2, X3 are 3, 50°C and mg/ml, respectively. The DSR 
and IR studies of GP-PMS by the optimal settings demonstrated that GP and 
phospholipids in the GP-PMS were combined by non-covalent bond, not forming a new 
compound. GP-PMS significantly increased the lipophilicity of GP, and P of GP-PMS in 
n-octanol and water was about 20 multiples more than that of GP material. The study 
concluded that pharmacosomes could be an alternative approach to improve the absorption 
and permeation of biologically active constituents. 
 
10.Ping A et al (2005)., 29 Designed and development didanosine pharmacosomes from 5′-
cholesterylsuccinyldideoxinosine (CS-ddl). The lipophilic prodrug of didanosine was 
prepared using the tetrahydrofuran injection method. Configuration and particle size were 
observed through TME and AFM, and in-vivo behavior of the pharmacosomes was 
investigated in rats by determination of CS-ddl and ddl in plasma and tissue with HPLC. 
The ddl pharmacosomes were particles of tube-shape with a particle size of about 200 
nm;t1/2 of CS-ddl in plasma of rat was 7.64 min, CS-ddl concentrated in liver quickly after 
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iv administration, its elimination from target tissue was slow, t1/2 of CS-ddl in liver was 10 
days. The study concluded that the ddl pharmacosomes showed obvious liver targeting and 
sustained-release effect in the target tissues. 
 
11.Jin Guang et al (2005).,
 
30
 Prepared acyclovir pharmacosomes by tetrahydrofuran 
injection and investigated the various properties. The negatively charged pharmacosomes 
were nanometer vesicles based on analysis of transmission electron scanning calorimetry. 
The effects of centrifugation and heating on stability of pharmacosomes were weak. 
Freezing and lyophilisation disrupted pharmacosomal structure. The amphiphilic 
pharmacosomes were inserted into rabbit erythrocyte membranes and it led to hemolysis. 
Plasma protein in blood absorbed pharmacosomes or interfered the interaction with 
erythrocytes to reduce hemolytic reaction. 
 
12.Zhang Z R et al (2001)., 31 Attempted to optimize the preparation of 3′, 5′-dioctanoyl-
5-fluro-2′-deoxyuridine pharmacosomes. The study found that the drug-
phosphatidylcholine ratio, pluronic F-68 concentration, and glycerol tri stearate 
concentration have an influence on the mean particle size, entrapment ratio and drug 
loading. The study also revealed that the pharmacosomes can improve the ability of a drug 
to cross the blood-brain barrier and act as a promising drug-targeting system for the 
treatment of central nervous system disorders. 
 
13.Raikhman L M et al (2002).,32 Developed pharmacosomes of ibuprofen to improve 
the bioavailability as well as to minimize the gastrointestinal toxicity of free ibuprofen. 
The pharmacosomes of ibuprofen were prepared by conjugation of free ibuprofen with 
phosphatidylcholine (80%) in two different molar ratios (1:1 and 1:2). The water solubility 
of ibuprofen pharmacosomes were found to be much better than free ibuprofen. The free 
ibuprofen showed only 67.96% drug release at the end of 4 hour dissolution study. The 
study concluded that the solubility and dissolution of ibuprofen can be enhanced by 
pharmacosomes formulation which could also minimize the gastrointestinal toxicity. 
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14.Vishal patel et al (2011)., 33 Designed, synthesized and characterized a prodrug of 
glycerol-skeleton lipid prodrug, which was 1-octadecyl-2-fluorouracil-N-acetyl-3-
zidovudine phosphoryl glycerol (OFZPG). The study revealed that the prodrug had 
suitable amphiphilicity. A kind of highly dispersed homogenous suspension system with 
high concentration was prepared by tetrahydrofuran (THF) injection method. OFZPG 
pharmacosomes were spheroidal. Antitumor activity of OFZPG pharmacosomes was 
investigated, in the three human colon cancer cells and it was better than that of 5-FU. The 
results indicates that the prodrug could degrade to the active compound efficiently, which 
could play an important role in pharmacodynamic action. OFZPG pharmacosomes played 
an important role in the antitumor activity. 
 
15.Sharma S et al (2010)., 34 An amphiphilic phyto-phospholipid complex were 
developed in order to enhance the delivery of poorly soluble drug (baicalein). The poor 
solubility and dissolution rate limits  its oral absorption and bioavailability. The 
baicalein-phospholipid complex (Ba-PLc) was prepared and evaluated for various 
physico-chemical parameters like drug loading, FT-IR, DSC,X-ray powder diffractometry, 
scanning electron microscopy, aqueous/n-octanol solubility and dissolution study. In the 
SME, the phospholipid complex was found to be fluffy and porous with rough surface 
morphology. FT-IR, DSC and XRD data confirmed the formation of phospholipid 
complex. The water /n-octanol solubility of baicalein was improved significantly in the 
complex. The result of the study concluded that the phospholipid complex may be 
considered as a promising drug delivery system for improving the absorption and overall 
bioavailability of the baicalein molecule. 
 
16.Shipra Duggal et al (2012).,34 Quercetin(3,3′,4′,5,7-pentahydroxyflavone), which is a 
polyphenolic flavonoid, shows several biological effects like anti-inflammatory, anti-
cancer, anti-proliferative, anti-mutagenic and apoptosis induction, but its use is limited due 
to its low aqueous solubility. To overcome this limitation, the phospholipids complex of 
quercetin was developed to improve its aqueous solubility for better absorption through 
the gastrointestinal tract which may improve its bioavailability. The quercetin-
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phospholipid complex prepared were evaluated for various physic-chemical parameters 
like infra-red spectroscopy, differential scanning calorimetry, X-ray powder diffraction, 
scanning electron microscopy, solubility studies and in-vitro antioxidant activity. The 
phospholipid complex of quercetin was found to be fluffy and porous with rough surface 
in SME, FTIR, DSC and XRPD data confirmed the formation of phospholipid complex. 
The water solubility of quercetin was improved by 12 folds in the prepared complex. 
There was no statistical difference between the quercetin complex and quercetin in the in-
vitro anti-oxidant activity, indicating that the process of complexation did not adversely 
affect the bioactivity of the active ingredient. 
 
17.Yi-Guang et al (2007).,36 The pharmacosomes of cholesterly –adipoyl didanosine 
(CAD) were prepared and the physical and chemical stability were evaluated. The 
pharmacosomes were prepared from the previously synthesized lipophilic prodrug of 
didanosine (CAD) using the tetrahydrofuran (THF) injection method. The morphology 
and particle size of pharmacosomes were evaluated using TEM and laser particle analyzer. 
The effects of heat, centrifugation and storage on the physical stability were also 
investigated. The degradation of prodrug in buffer solutions, carboxyl ester enzyme 
solution, rat plasma and liver homogenates was also evaluated. The prepared 
pharmacosomes were spherical vesicles with the size of 122nm and showed good physical 
stability. The degradation of prodrug was different in various environments. The half-life 
of CAD in rat liver homogenates was 23 hour. 
 
18.Ajay Semalty et al (2010)., 37 Prepared and characterized phospholipid complex of 
naringenin for effective drug delivery. Naringenin is a flavonoid specific to citrus fruits 
and possesses anti-inflammatory, anti-carcinogenic, and anti-tumor effects. But due to a 
lower half-life and rapid clearance from the body, frequent administration of the molecule 
is required. To improve the bioavailability and prolong its duration in body system, its 
phospholipid complexes were prepared. Naringenin was complexed with 
phosphatidylcholine in equimolar ratio, in presence of dichloromethane. The prepared 
phytosomes were evaluated for various physical parameters like FT-IR spectroscopy, 
differential scanning calorimetry, X-ray powder diffractometry, solubility, scanning 
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electron microscopy and the in-vitro drug release study. These phospholipid complex of 
naringenin were found to be irregular and disc shaped with rough surface in SEM. Drug 
content was found to be 91.7 %( w/w). FTIR,1H NMR, DSR and XRPD data confirmed 
the formation of phospholipid complex. Water solubility of naringenin improved in the 
prepared complex. Unlike the free naringenin (which showed a total of only 27% drug 
release at the end of 10 hours), niringenin complex showed 99.80% release at the end of 
10 hour of dissolution study. It was concluded that the phospholipid complex of 
naringenin is of potential use for improving bioavailability. 
 
19.Prabhu S et al (2005).,38 The study was carried out to prepare novel lipid based 
formulations of a model drug, piroxicam (PXCM), which is poorly water soluble non-
steroidal anti-inflammatory drug (NSAID) using 1,2-dimyristoyl-sn-glycerol-3-
phosphatidylcholine (DMPC) phospholipid alone, and in combination with polyethylene 
glycol (PEG 4600). Lipid-based drug delivery systems were prepared by using 
conventional method of preparation and were evaluated for the in-vitro dissolution 
behavior, absorption via Caco-2 cell monolayers and the stability of formation over a 12-
month period. The physical characterization studies using differential scanning 
calorimetry (DSC) were also performed. Formulations of PXCM were prepared by using 
DMPC in different combinations and a mixture of DMPC and PEG 4600. Dissolution 
studies showed an increase in dissolution rate and extent of the PXCM from all complexes 
when compared to be control. DSC studies further confirmed the dissolution behavior of 
these formulations demonstrating different levels of amorphous to crystalline nature. 
Results of HPLC analysis from Caco-2cell culture studies showed increase in transport of 
PXCM from all formulations, when compared to control. 
 
20.Mali Kamalesh et al (2014)., 39   Formulated pharmacosomes of ketoprofen by 
conventional solvent evaporation technique to increase the solubility and bioavailability in 
different media along with minimizing the GI disturbances. Two different ratio of drug: 
phospatidylcholine in 1:1 and 1:2 were used to form pharmacosomes. Drug content was 
found to be 93.28% w/w for ketoprofen phospholipid complex (1:1) and 85.44% w/w for 
ketoprofen phospholipid complex (1:2). Further studies were carried out by optimizing the 
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ketoprofen phospholipid complex (1:1) ratio. Scanning electron microscopy and particle 
size analysis revealed difference between the formulations as to their appearance and size 
distribution and DSC examination showed the amorphous nature of the drug. Solubility of 
pure ketoprofen improved which exhibited an increase of 2.09 fold. Dissolution profile of 
the prepared complex was found to be 93.30% which was much better than pure 
ketoprofen which was 49.77% in 8 hrs. Formulation of ketoprofen into pharmacosome 
was found to be a positive approach for improving solubility and bioavailability of the 
poorly soluble drug. 
 
21.Idha Kusumawati et al (2011).,40  Prepared and evaluated the phospholipid complex 
of kaempferia galangal rhizome extract using phosphatidylcholine to improve the 
bioavailability of its constituents. Characteristics and analgesic activity of the extract and 
its marker compound, ethyl p-methoxycinnamate(EPMS), were compared to their 
phospholipid complex (F.Extract and F.EPMS). Characteristics of the free form and their 
complexes were analysed by DTA and SEM. Their analgesic activity was determined 
using writhing test. The complex showed better analgesic activity compared to the free 
form of the both extract and EPMS at an equivalent dosage. 
 
22.Ajay Semalty et al (2010).,41  Developed and characterized aspirin-phospholipid 
complex for improved oral drug delivery. Aspirin is poorly soluble in water and causes GI 
irritation. To improve the solubility (and hence the bioavailability) and minimize the GI 
irritation, its complexes with soya-phospholipid-80% (in 1:1 molar ratio) were prepared in 
an organic solvent and evaluated for solubility, drug content, scanning electron 
microscopy (SEM), FT-IR spectra, X-ray diffraction, differential scanning calorimetry and 
in-vitro dissolution study. Aspirin-phospholipid complex were found to be disc shaped 
with rough surface in SEM. Drug content in a complex was found to be 95.60%. DSC 
thermograms, XRD and FTIR confirmed the formation of phospholipid. Solubility of the 
prepared complex was found to be improved. Aspirin complex and pure aspirin showed 
90.93% and 69.42% of drug release at the end of 10 hrs dissolution study in pH 1.2 acid 
buffer. It was concluded that the phospholipid complex of aspirin is of potential use for 
improving the solubility of aspirin and hence its bioavailability. 
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23.Jessy Shaji et al (2014).,42  To enhance the transdermal penetration of the poorly 
water-soluble NSAID, Pirovicam, it was encapsulated it into a nanocarrier namely 
transferosomes. In order to increase the drug encapsulation into the transferosomes, water 
soluble cyclodextrin complex solutions of drug were entrapped into aqueous phase of 
stable unilamellar transferosomes in addition to incorporating into the liposomal bilayer by 
the thin firm hydration method and sonication. TEM measurement suggested that, the drug 
cyclodextrin complexes were successfully loaded into the transferosomes without 
affecting their morphology. At optimal conditions, the mean particle size of double loaded 
transferosomes was ~158.7 nm and entrapment efficiency of ~85.7% was achieved. The 
entrapment efficiency was increased when compared with batches not containing the 
cyclodextrin complexes. The optimized formulation shows no interaction with skin 
components which was confirmed by skin-vesicles interaction and ex-vivo corrosion 
studies. Transferosomes containing cyclodextrin inclusion complexes released more drug 
than transferosomes encapsulating non-complexed drug, the drug release being related to 
entrapment efficiency. The formulation also demonstrated superior anti-inflammatory 
activity in rodents in in-vivo carrageenan induced rat paw edema model. 
 
24.Chandra A et al (2008).,43 Prepared the pharmacosomes of piroxicam by conventional 
technique, employing maltodextrin and sorbital as base. The morphology of the 
proniosomes was studied by scanning electron microscopy. The lipid vesicles were 
evaluated for entrapment efficiency and vesicles size. It was observed that span 60 based 
formulation produced vesicles of smallest size and higher entrapment efficiency while 
those of span 80 produced vesicles of least entrapment efficiency. Incorporation of lecithin 
further enhanced entrapment efficiency. Permeation of losartran from proniosomes based 
reservoir type transdermal gel formation across excised rat abdominal skin was 
investigated using keshery chain diffusion cell. There was significant reduction in 
carrageenan induced rat paw inflammation compared to control. Anti-inflammatory 
studies revealed that proniosome based transdermal drug delivery system of losartan were 
promising carriers for delivery of losartan. 
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25.Sujitha B et al (2014).,44  Formulation and evaluated ethosomes containing losartan by 
using phospholipid, ethanol, propylene glycol and distilled water by cold method. 
Prepared ethosomal vesicles were evaluated for vesicular size, shape, entrapment 
efficiency, in-vivo skin diffusion, skin irritation and stability studies. Scanning electron 
microscopy and size analysis results showed that ethosomes were in spherical, unilamellar, 
nanometric size. The optimized formulation showed highest entrapment efficiency of 
73.59%. This optimized formulation of ethosomes vesicles was further formulates to gel 
by using carbopol. This kinetic study was found to fit in first order model and observed no 
remarkable symptoms on skin from skin irritation study. 
 
26.Rajesh N et al (2010).,45  The study was aimed to minimize the local gastrointestinal 
irritation which is one of the major size efforts to piroxicam after oral ingestion by kinetic 
control of drug release. Piroxicam was incorporated into into the biocompatible blends of 
micro crystalline cellulose (MCC) and hydroxyl methyl cellulose (HPMC) matrix pellets 
using pelletization technique using PVP as binder. The prepared pellets were subjected to 
micromeritic properties, SEM, DSC, FTIR and stability studies. Solid, free flowing matrix 
pellets were obtained. More than 98% of the isolated pellets were of particle size range 
1.35 to 1.44 mm. The obtained matrix pellets had smooth surfaces, with free flowing and 
good packing properties. Scanning electron microscopy (SEM) confirmed their spherical 
structures. Drug loaded MCC/HPMC pellets was stable and compatible as confirmed by 
DSC and FTIR studies. The released of drug from the blends was controlled up to 20 hrs. 
 
27.Muhammad D. Hussian et al (2010).,14    Evaluated the modulation effects of 
phospholipids on enhancing the dissolution and oral bioavailability of piroxicam 
formulations. On the basis of in-vitro dissolution studies, dimyristoylphosphatidylglycerol 
(DMPG) was ranked as the first potent dissolution rate enhancer for the model drug. Thus, 
the solid dispersion of varying piroxicam/DMPG ratios were prepared and further 
investigated. Within the concentration range studied (6.4-16.7 wt %), the dissolution rate 
of piroxicam from the solid dispersion appeared to increase as a function of the carrier 
weight fraction. The oral bioavailability of piroxicom from the DMPG-based formulations 
in rats was found to superior to that of the control. Hence, DMPG was regarded as the 
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most promising carrier-phospholipid for enhancing oral bioavailability of piroxicom and 
potentially other Class II drugs. 
 
28.Sayed H. Auda et al (2010)., 46 Formulated and characterized piroxicam containing 
polymer films for dermal use. The used polymers were eudragit containing polymer films 
for dermal use. The used polymers were Eudragit types namely eudragit RL100, 
RS100,L100 and Eudragit S100. The medicated films consisting of drug and carrier were 
prepared. The carrier consisted of one or two polymers. The physicochemical 
characterization was done by IR spectroscopy, DSC and X-ray diffractometry for 
piroxicam polymeric films and their corresponding physical mixtures as well as the 
untreated drug and polymer powders to investigate the drug polymer powders to 
investigate the drug polymer interaction. The results indicated the presence of molecular 
interactions between piroxicam and both Eudragit L100 and Eudragit S100 and no 
interactions were found between piroxicam and Eudragit RL100 or Eudragit RS100.in-
vitro drug release from Eudragit films was also carried out which revealed that the drug 
release from hydrophilic polymers is faster than that from hydrophobic ones.       
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                                         AIM AND OBJECTIVES  
             The aim of the study is to prepare pharmacosomes containing Losartan using 
different concentrations of soya lecithin by solvent evaporation technique in order to 
achieve a prolonged release of drug and also to improve the bioavailability of the drug. 
 
  The objectives of the study are: 
 To formulate pharmacosomes of losartan by solvent evaporation method. 
  To characterize the prepared pharmacosomes by different methods 
including preformulation studies, drug content determination and 
solubility studies. 
 To prepare capsules containing the pharmacosomes. 
 To carry out the quality control tests for capsules. 
 To perform the vesicle shape determination, X-ray powder diffraction 
analysis (XRD) and drug release kinetic data analysis of the optimized 
formulation.  
 To carry out the stability studies of the optimized formulation of 
pharmacosome as per ICH guidelines.  
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                                                        PLAN OF WORK 
 
1. Drug selection. 
2. Formulation of pharmacosomes of Losartan by solvent evaporation technique. 
3. Preformulation studies of pharmacosomes 
 FT-IR 
 Angle of repose 
 Bulk density 
 Tapped density 
 Drug content determination 
 Solubility studies 
4.  Filling of the capsules with pharmacosomes. 
5. Post formulation studies of capsules. 
 Weight variation 
 Disintegration test  
 In-vitro dissolution study 
6. Perform the vesicle shape determination and X-ray powder diffraction analysis 
(XRD) of the optimized formulation. 
7. Carry out drug release kinetic data analysis and stability studies of the optimized 
formulation of pharmacosome as per ICH guidelines. 
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DRUG PROFILE52, 53, 54 
                        LOSARTAN 
 
 CHEMICAL STRUCTURE 
 
 
 
 CHEMICAL NAME 
[2-butyl-5-chloro-3[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-
yl]methanol 
 
 MOLECULAR WEIGHT 
422.917g/mol 
 
 MOLECULAR FORMULA 
C22H23CIN6O 
 
 CATEGORY 
Agents acting on the renin- Angiotensin system 
Antihypertensive Agents 
Anti-Arrhythmia Agents 
Cardiovascular Agents 
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 DESCRIPTION 
Physical Description - Solid 
Color - Light yellow solid  
Solubility - It is water soluble, sparingly soluble in ethyl acetate, butyl acetate, and 
cyclohexane, and the solubility in these three solvent varys little with the 
temperature. 
 
 DOSE 
Diabetic Nephropathy 
 Initial dose: 50 mg orally once a day 
 Maximum dose: 100mg orally once a day 
 
Hypertension 
 Initial dose: 50 mg orally once a day 
 Maximum dose: 100mg orally once a day 
 
 MELTING POINT 
184°C 
 
 PROTEIN BINDING 
99.7% 
 
 ORAL BIOAVAILABILITY 
25-30% 
 
 
 STORAGE 
Store it in well-closed, light resistant container. 
 
 
 ROUTES OF ADMINISTRATION 
Oral 
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 HALF LIFE 
6-9 hours 
 
 METABOLISM 
Hepatic 
 
 EXCRETION 
Renal and fecal 
 
 MECHANISM OF ACTION 
Losartan is a selective, competitive angiotensin II receptor type 1 (AT1) antagonist, 
reducing the end organ responses to angiotensin II. Losartan administration results 
in a decrease in total peripheral resistance (afterload) and cardic venous return 
(preload). All of the physiological effects of angiotensin II, including release of 
aldosterone, are antagonized in the presence of Losartan. Reduction in blood 
pressure occurs independently of the status of the rennin-angiotensin system. As a 
result of Losartan dosing, plasma renin activity increases due to removal of the 
angiotensin II. 
 
 CONTRAINDICATION 
The drug is contraindication in patients with: 
 High amount of potassium in the blood, Renal artery stenosis, abnormally 
low blood pressure, liver problems, mild to moderate kidney impairment, 
pregnancy, decreased blood volume. 
 
 SIDE EFFECTS 
Abdominal or stomach pain, anxiety, bladder pain, bloody or cloudy urine, chills, 
cold sweats, coma, cool, pale skin, shortness of breath, irregular heartbeat, difficult 
breathing, increase hunger, depression. 
 
 TOXICITYHypotension and tachycardia; Bradycardia could occur from 
parasympathetic (vagal) stimulation. 
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 PRECAUTIONS 
Pregnancy: 
It can harm unborn baby. Use an effective form of birth control to keep from 
getting pregnant. 
 
Nursing mothers: 
Safety and effectiveness in nursing mothers have not been established 
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EXCIPIENT PROFILE58, 59 
SOYA LECITHIN 
 SYNONYM 
Mixed soybean phosphatides, ovolecithin, phospholipon, soybean phospholipids 
and vegetable lecithin 
 
 CHEMICAL NAME 
1, 2-diacyl-sn-glycero-3-phosphocholine 
 
 CHEMICAL STRUCTURE 
 
 
 
 CHEMICAL COMPOSITION 
Contains 21% phosphatidylcholine, 22% phosphatidylethanolamine and 19% 
phosphatidylinositol, along with other components 
 
 DESCRIPTION 
Lecithins vary greatly in their physical form, from viscous semi liquids to powders, 
depending upon the free fatty acid content. They may also vary in colour from 
brown to light yellow, depending upon whether they are bleached or unbleached or 
on the degree of purity. 
 
 FUNCTIONAL CATEGORY 
Emollient, emulsifying agent and solubilising agent 
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 SOLUBILITY 
Soluble in aliphatic and aromatic hydrocarbons, halogenated hydrocarbons, 
mineral oil, and fatty acids. Sparingly soluble in ethanol (95%). They are 
practically insoluble in cold vegetable and animal oils, polar solvents, and water. 
When mixed with water, however, lecithins hydrate of form emulsions. 
 
 DENSITY 
0.5g/cm3 
 
 ISOELECTRIC POINT 
3.5 
 
 COMPATIBILITY 
Incompatible with esterases owing to hydrolysis 
 
 STABILITY 
Lecithins decompose at extreme pH. They are also hygroscopic and subject to 
microbial degradation. When heated, lecithins oxidize, darken, and decompose. 
Temperatures of 160-180°C will cause degradation within 24 hours. 
 
 FLAMMABILITY 
Low  
 
 MOISTURE CONTENT 
Are hygroscopic 
 
 SPECIFIC GRAVITY 
0.97g/cm3 
 STORAGE 
Should be stored in well-closed containers protected from light, moisture and 
oxidation. Purified solid lecithins should be stored in tightly closed containers at 
subfreezing temperatures. 
 
Excipient Profile 
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 APPLICATIONS  
 Lecithins are used in wide variety of pharmaceutical applications like 
aerosol inhalations, IM injections and oral suspension and are also used in 
cosmetics and food products. 
 Lecithins are mainly used in pharmaceutical products as dispersing, 
emulsifying, and stabilizing agents, and are included in intramuscular and 
intravenous injections, parenteral nutrition formulations, and topical 
products such as cream and ointments. 
 Lecithins are also used in suppository bases to reduce the brittleness of 
suppositories, and have been investigated for their absorption-enhancing 
properties in an intranasal insulin formulation. 
 Lecithins are also commonly used as a component of enteral and parenteral 
nutrition formulations. Lecithin is a required component of FDA-approved 
infant formulas. 
 Therapeutically, lecithin and derivatives have been used as a pulmonary 
surfactant in the treatment of neonatal respiratory distress syndrome. 
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MATERIALS AND METHODS 
 
Table 1: LIST OF MATERIALS USED AND THEIR SOURCES 
 
 
MATERIALS 
 
 
SOURCES 
 
Losartan 
 
Microlabs,Chennai 
 
Soya lecithin 
 
HiMedia Laboratories, Nashik 
 
Dichloromethane 
 
Loba Chemie, Mumbai 
 
Hydrochloric acid 
 
SD Fine chem. Ltd, Mumbai 
 
Chloroform 
 
HiMedia Laboratories, Mumbai 
 
                                     
 
Table 2: LIST OF EQUIPMENTS USED 
 
EQUIPMENTS 
 
SUPPLIERS / MANUFACTURES 
 
 
FT/IR Spectroscopy/4100 
 
 
Jasco,Johannesburg, South Africa 
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Rotary vaccum evaporator 
 
 
Superfit,India 
 
UV-visible double beam spectrophotometer 
 
Shimadzu,Shimadzu corporation, Philippines 
 
 
Bulk and tapped density apparatus 
 
Thermonik,Campbell 
electronics,Mumbai,India 
 
 
Weighing balance 
 
Shimadzu,Shimadzu corporation, Philippines 
 
 
Heating mantle 
 
Sunbim, India 
 
 
Disintegration apparatus 
 
Tab machines, Mumbai, India 
 
 
Dissolution apparatus 
 
Tab machines, Mumbai, India 
 
 
Stability chamber 
 
 
Technico, Chennai, India 
 
pH meter 
 
EUTCH Instruments, India 
 
 
Scanning electron microscope 
 
 
JEOL,Japan 
 
XRD-6000 diffractometer 
 
Shimadzu, Japan 
 
 
 Materials and Methods 
 Dept of Pharmaceutics,KMCH College of Pharmacy                                               33 
 
 
DETERMINATION OF λmax 1 
The stock solution of 100µg/ml was prepared by dissolving 100mg of pure Losartan in 100ml 
of pH 7.4 phosphate buffer. From the stock solution, 10ml was taken and futher diluted to 
100ml with the buffer solution. The prepared solution was then scanned in a wavelength 
range of 200-400nm, to find the maximum absorbance. The maximum wavelength was found 
to be 234nm and was used for further studies. 
DETERMINATION OF STANDARD CURVE14 
 The serially diluted stock solution was obtained in the range of 2-10µg/ml by taking 
0.2, 0.4, 0.6, 0.8 and 1 ml from the stock solution, into 100ml volumetric flask. 
 The final solution is made by using phosphate buffer of pH 7.4. 
 The serially diluted solutions were measured in a UV spectrometer at 331nm of the 
drug. 
 The calibration curve was plotted by taking absorbance on y-axis and concentration in 
µg/ml on x-axis, to find the slope. 
 
PREPARATION OF PHARMACOSOMES OF LOSARTAN BY SOLVENT 
EVAPORATION TECHNIQUE20 
To prepare the pharmacosomes of losartan, it was first acidified so that the active 
hydrogen might be available for complexation. Losartan was prepared by acidification of an 
aqueous solution of losartan using 0.1N hydrochloric acid. It was then extracted into 
chloroform and subsequently recrystallized. Phosphatidycholine (PC) complex was prepared 
by associating losartan with PC in various molar ratios. The accurately weighed PC and 
losartan were placed in a 100 ml round bottom flask and dissolved in sufficient amount of 
dichloromethane. The mixture was refluxed for one hour. Then the solvent was evaporated 
off under vacuum at 40°C in a rotary vacuum evaporator. The dried residues were collected 
and placed in vacuum dessicator for three days and then subjected to characterization. 
                      
 
 Materials and Methods 
 Dept of Pharmaceutics,KMCH College of Pharmacy                                               34 
 
    
Table 3: Formulation table of losartan pharmacosomes 
 
 
 
PREFORMULATION STUDIES 
The discovery and development of new chemical entities (NCEs) into stable, bioavailable, 
marketable drug products is a long, but rewarding process. Once a NCE is selected for 
development, choosing the molecular form that will be the active pharmaceutical ingredient 
(API) is a critical milestone because all subsequent development will be affected by the 
decision. A well- designed preformulation study is necessary to fully characterize molecules 
during the discovery and development process so that NCEs have the appropriate properties, 
and there is an understanding of the deficiencies that must be overcome by the formulation 
process.63 The procedure of each preformulation test suitable for capsule is given below. 
COMPATIBILITY STUDIES 
IR spectra matching approach was done for detecting any possible chemical interaction 
between drug and excipient. A physical mixture of drug and excipient was prepared and 
mixture with the suitable quantity of potassium bromide. About 100mg of mixture was 
compressed to from a transparent pellet using a hydraulic press at 6 tons pressure. It was  
 
Ingredients 
 
 
F1 
 
F2 
 
F3 
 
F4 
 
F5 
 
F6 
 
F7 
 
Losartan: 
Soyalecithin 
 
 
1:1 
 
1:1.5 
 
1:2 
 
1:2.5 
 
1:3 
 
1:3.5 
 
1:4 
 
Dichloromethane 
(ml) 
 
20 
 
20 
 
20 
 
20 
 
20 
 
20 
 
20 
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scanned from 4000 to 400 cm-1 in FTIR spectrometer. The IR spectrum of pure drug and 
matching was done to detect any appearance or disappearance of peaks. 
ANGLE OF REPOSE 
It is the maximum angle that can be obtained between the free standing surface of a powder 
heap and the horizontal plane. It was determined by the funnel was kept vertically at a 
specified height and the funnel bottom was closed. Weighed accurately 10mg of the granules 
and filled into the funnel. The funnel height was adjusted as the tip of the funnel touches the 
apex of the heap of powder. The sample was allowed to pass through the funnel freely onto 
the surface.63 Then the powder cone diameter was measured and angle of repose was 
calculated by using the following formula. 
                                                        Tan θ =h/r                   (1) 
 
Therefore, 
                Θ = Tan-1 (h/r) 
Where,    θ = angle of repose 
                h = height of the cone 
                 r = radius of the cone 
Table 4: Standard values for Angle of repose 
 
Angle of repose in degrees 
 
Type of flow 
 
<25 
 
Excellent 
 
25-30 
 
Good 
 
30-40 
 
Satisfactory 
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BULK DENSITY 
The bulk density was determined by pouring presieved (#40 mesh) powder into a 
graduated cylinder via a large funnel and measured the volume and weight.63 
It was calculated in gm/cm3 by the formula, 
                                 Bulk Density (δ0) =M/V0                                                                    (2) 
               M= Mass of the sample/ weight of sample 
               V=Apparent unstirred volume/ Bulk volume. 
TAPPED DENSITY 
Tapped density was determined by placing a know amount of powder in graduated 
cylinder on the mechanical tapper apparatus which was operated for a fixed number of taps 
(~1000) until the powder bed volume had reached a minimum. The tapped density was 
calculated by using the weight of the sample in the cylinder and that minimum volume. 
The tapped density was calculated in gm/cm3 by the formula, 
                                Tapped density (δt) =M/Vf                                                      (3) 
                        M=Weight of the sample 
                        Vf= Tapped volume 
COMPRESSIBILITY INDEX/CARR’S INDEX 
The compressibility index of the powder was determined by using the following formula: 
             Compressibility index (%) = [(TBD-LBD) ×100]/TBD                          (4)  
                 LBD=Loose bulk density 
                 TBD=Tapped bulk density 
 
>40 
 
Poor 
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HAUSNER’ S RATIO: 
Hausner ratio was calculated by using the following formula63. 
                           Hausner’s ratio= (δt/δ0)                                          (5) 
                δt = Tapped density 
                δ0 = Bulk density 
 
Table 5: Scale of flow ability for compressibility index and Hausner’s Ratio 
 
CARR’S INDEX 
 
HAUSNER’S RATIO 
 
TYPE OF FLOW 
 
5-15 
 
1.05-1.18 
 
Excellent 
 
12-16 
 
1.14-1.20 
 
Good 
 
18-21 
 
1.22-1.26 
 
Fair-passable 
 
23-35 
 
1.30-1.54 
 
Poor 
 
33-38 
 
1.50-1.61 
 
Very poor 
 
>40 
 
>1.67 
 
Very very poor 
  
DRUG CONTENT DETERMINATION 
For the determination of the drug content in losartan pharmosome, the complex 
equivalent to 50 mg losartan was weighed and added into a volumetric flask with 100 ml of 
pH 7.4 phosphate buffer. Then the volumetric flask was stirred continuously for 24 hours on 
a magnetic stirrer. At the end of 24 hr, the dilutions were made suitably and it was measured 
for the drug content at 234nm UV spectrophotometrically.24 
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SOLUBILITY DETERMINATION 
To determine the change in solubility due to complexation, the apparent solubility of 
losartan and losartan pharmacosomes was determined by adding an excess amount of drug 
and pharmacosomes to 6 ml distilled water, 7.4 pH phosphate buffer and n-octanol in screw 
capped vials. The vials were then shaken at 25°C for 24 hr in a water bath. After equilibrium 
had been attained, the saturated solutions obtained were centrifuged to remove the excess 
drug (15 min, 1000 rpm). The supernatant was filtered immediately and rapidly and diluted 
suitably with same solvent to prevent crystallization. The filtered and diluted solution were 
then analyzed spectrophotometrically at 234nm.20 
POST FORMULATION STUDIES 
WEIGHT VARIATION TEST 
Select 20 capsules randomly. Weigh an intact capsule. Open it without losing any part 
of the shell and remove the contents as completely as possible. Weigh the shell. The 
difference between the weighing gives the weight of the shell. The difference between the 
weighing gives the weight of the contents. Repeat the procedure with the remaining 19 
capsules. Calculate the average weight . Not more than two of the individual weights deviate 
from the average weight by more than the percentage deviation show in the table and none 
deviates by more than twice that percentage.63,64 
 
Average weight of formulation 
 
Percentage Deviation 
 
Less than 300mg 
 
±10 
 
300mg or more 
 
±7.5 
 
DISINTEGRATION TEST: 
This test was done by using disintegration apparatus (Tab machine, Mumbai). Place 
one capsule in each of the 6 tubes of the basket and add a disc to each tube. Suspend the 
assembly in the beaker containing distilled water. The distilled water in that apparatus was 
maintained at 37±2°C. The assembly should be raised and lowered between 28-32 cycles per 
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minute. The time taken for complete disintegration of the complete disintegration of the 
capsule with no palpable mass remaining in the apparatus was measured and recorded.63,64 
If one or two capsule fail to disintegrate, repeat the test on 12 additional capsules; 
NLT 16 of the total 18 capsules tested should disintegrate. 
DISSOLUTION: 
This test was carried out by using USP XXIV dissolution test apparatus Type I 
(basket apparatus). The stirring speed was maintained at 50 rev/min and the temperature was 
maintained at 37°C±0.5°C. The release study for the capsule was carried out by keeping the 
capsule was carried out by keeping the capsules for 10hours in the dissolution medium of pH 
7.4 phosphate buffer solution (900ml). At predetermined time intervals, 10ml of sample was 
withdrawn and was replaced with 10ml fresh buffer solution. The absorbance of the sample 
was measured by using double beam spectrophotometer at 331nm. The cumulative release of 
the sample was calculated by using suitable equations with the help of the standard curve.63,64 
 
X-RAY POWDER DIFFRACTION (XRD) ANALYSIS: 
The crystalline state of Losartan in the different samples was measured using X-ray 
powder diffractometer (Shimaszu, Japan) at CRL, Karunya University, Coimbatore. The 
powder sample was placed in an aluminium sample holder. The X-ray generator was operated 
at 40kV tube voltages and 30mA of tube current, using the Ka lines of cooper as the radiation 
source. The scanning angle ranged from 10 to 90° with a scan speed of 10° min-1. The drug, 
phosphatidylcholine and the pharmacosome were analyzed with X-ray diffraction .21 
SCANNING ELECTRON MICROSCOPY (SEM) ANALYSIS: 
To detect the surface morphology of the pharmacosome, SEM of complex was 
performed by Scanning Electron Microscope JSM 6390 (JEOL, Japan) at CRL, Karunya 
University, Coimbatore. Sample was kept on an SEM stub using double-sided adhesive tape 
at 50mA for 6min through a sputter (KYKY SBC-12, Beijing, china). A scanning electron 
microscope with a secondary electron detector was used to obtain digital images of the 
pharmacosomes.39 
DRUG RELEASE KINETIC ANALYSIS65 
 Materials and Methods 
 Dept of Pharmaceutics,KMCH College of Pharmacy                                               40 
 
To study the release kinetics, data obtained from in-vitro drug release studies were plotted in 
various kinetic models: 
Zero order (Equation 7) as cumulative amount of drug released vs. time 
First order (Equation 8) as log cumulative percentage of drug remaining vs. time 
Higuchi model (Equation 9) as cumulative percentage of drug released vs. square root of 
time. 
                               C= K0 t                                                         (7) 
Where 
K0  is the zero-order rate constant expressed in units of concentration /time 
T is the time in hours. 
A graph of concentration vs. time would yield a straight line with a slope equal to K0 and 
intercept the origin of the axis. 
                     Log C= Log C0- kt/2:303                                         (8) 
Where, 
C0 is the initial concentration of drug, 
K  is the first order constant , and t is the time. 
 
                      Q= Kt1/2                                                                       (9) 
Where, 
K: is the constant reflecting the design variables of the system 
t: is the time in hours. 
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MECHANISM OF DRUG RELEASE66 
To evaluate the mechanism of drug release form the capsule , data of drug release 
were plotted in Korsmeyer peppas equation (Equation 10) as log cumulative percentage of 
drug released Vs. log time , and the exponent n and was calculated through the slope of the 
straight line. 
                                  Mt-M∞= Ktn                      (10) 
Where 
Mt/M is the fractional solute release, 
T is the release time, 
K is a kinetic constant characterizes the mechanism of release of tracers. 
If the exponent n=0.45, then the drug release mechanism is Fickian diffusion, and if 0.45≥ n 
≥ 0.89, then it is non-Fickian or anomalous diffusion. An exponent value of 0.89 is indicative 
of Case-II Transport or typical zero-order release. 
STABILITY STUDIES 
       Stability of a drug in a dosage form at different environmental conditions is important, 
because it determines the expiry date of that formulation. Hence, the stability of the drug in 
the pharmacosome was studied. Stability studies were conducted according by storing the 
capsules at 40°C± 2°C, 70% RH ± 5% for 45 days. The samples were withdrawn at initial, 
30th & 45th day and analyzed suitably for the physical characteristics, drug content and 
cumulative drug release. 
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RESULTS AND DISCUSSION 
CALIBRATION CURVE OF LOSARTAN 
 The Ȝmax of Losartan pure drug was determined by scanning the prepared solution 
in the wavelength range of 200-400nm. The maximum wavelength was found to be 
234nm. The calibration curve of losartan was constructed by dissolving the drug in pH 7.4 
phosphate buffer. The linearity of the curve was found in the concentration range of 2-
10ȝg/ml. A regression coefficient (R2) value of 0.9989 
Table: 6 Calibration curve data of Losartan 
 
 
 
 
 
 
 
 
 
 
 
Fig 1: Calibration curve of Losartan 
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COMPATABILITY STUDIES 
 The IR spectra of pure drug, losartan and the excipients, soya lecithin was analyzed 
and composed with IR spectra obtained for the mixture. It was found that the spectra of the 
drug with excipient showed all the characteristic peaks of Losartan suggesting that there 
was no compatability problem between the drug and the excipient. 
 
 
 
Fig 2: IR spectrum of Losartan pure drug 
 
 
 
Fig 3: IR Spectrum of Losartan + Soya lecithin 
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  Table 7: Characteristic peak of Losartan and soya lecithin 
 
 
 
 
 
 
 
 
 
PREFORMULATION STUDIES 
 The preformulation parameters like angle of repose, bulk density, tapped density, 
Hausner’s ratio and carr’s index were studied to evaluate the flowablity and 
compressibility of the powder formulation. 
Table: 8 Results of preformulation studies 
 
 
FORMULATION 
ANGLE 
OF 
REPOSE 
BULK 
DENSITY 
(gm/cm3) 
TAPPED 
DENSITY 
(gm/cm3) 
F1 24º15ꞌ 0.554 0.624 
F2 26º53ꞌ 0.401 0.453 
F3 24º82ꞌ 0.500 0.570 
F4 27º08ꞌ 0.433 0.500 
F5 28º30ꞌ 0.454 0.525 
F6 27º56ꞌ 0.415 0.500 
SPECIFICATION WAVE NUMBER (CM-1) 
Losartan PX+ Soya lecithin 
 
C-Cl Stretching 
 
762.39 
 
762.22 
 
C-N Stretching 
 
1422.5 
 
1408.60 
 
C-H Stretching 
 
2955.12 
 
2953.59 
 
N-H Stretching 
 
3358.14 
 
3281.82 
 
-OH Stretching 
 
1358.19 
 
1358.70 
 
C=C Stretching 
 
1581.49 
 
1579.32 
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F7 27º63ꞌ 0.500 0.624 
 
 The preformulation study of the prepared losartan pharmacosomes powder showed 
followings: 
Angle of repose at a range between = 24°15′ to 27°30′ 
Bulk density at a range between = 0.41gm/cm3 to 0.50gm/cm3 
Tapped density at a range between = 0.453gm/cm3  to 0.624gm/cm3 
The above values indicates that the sample have good flow character. All the 
results were within the prescribed limits. F1 formulation showed the best flow property. 
DRUG CONTENT STUDIES 
 The drug content of losartan in the pharmacosomes was estimated by UV 
spectrophotometery at 234nm using pH 7.4 phosphate buffer.  
Table 9: Results of drug content studies 
 
       
 
 
 
 
 
 
 
 
 
 
The drug content of losartan in the complex was found to be in the range of 
88.60% - 96.83% indicating the presence of an acceptable amount of drug in the 
formulations. The pharmacosomes showed a high percentage of drug loading, which is a 
 
FORMULATION   
 
DRUG CONTENT     
(%w/w) 
F1 96.83 
F2 96.12 
F3 93.38 
F4 93.56 
F5 90.81 
F6 90.04 
F7 88.60 
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prime advantage over liposomes. The percentage of drug loading decreased with an 
increase in the concentration of lipid. The formulation F1 showed the maximum drug 
content of 96.83%. 
SOLUBILITY STUDIES 
 The change in solubility of losartan due to complexation was determined by 
evaluating its solubility in water, pH 7.4 phosphate buffer and n-octanol solutions and was 
estimated by UV spectrophotometry at 234nm 
Table 10: Solubility profile in different media 
Formulation Solubility in Water 
(mg/ml) 
Solubility in pH 7.4 
phosphate Buffer 
(mg/ml) 
Solubility in  
n-Octanol (mg/ml) 
 
Pure Drug 
 
 
0.143 
 
0.196 
 
0.230 
 
F1 
 
 
0.787 
 
5.272 
 
5.975 
 
F2 
 
 
0.780 
 
5.150 
 
5.641 
 
F3 
 
 
0.651 
 
4.836 
 
5.283 
 
F4 
 
 
0.693 
 
3.950 
 
4.568 
 
F5 
 
 
0.527 
 
3.751 
 
4.190 
 
F6 
 
 
0.572 
 
3.863 
 
4.236 
 
F7 
 
 
0.616 
 
4.355 
 
4.586 
 
 The solubility of the losartan pharmacosomes was found to be much higher than 
the pure drug. The increase in solubility of Losartan in the complex can be explained by 
the solublilization theory resulted from the formulation of micelle in the medium and also 
by the amorphous nature of the complex. These amphiphilic surfactants (phospholipids)  
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may increase the solubility of the drug by their wetting and dispersion properties. The 
formulation F1 exhibited the highest degree of solubility. 
 
POST FORMULATION 
Table 11: Results of post formulation studies 
 
FORMULATION 
X 
WEIGHT 
VARIATION 
(mg) 
DISINTEGRATION 
TIME 
(Sec) 
F1 41±3.1 224 
F2 49±2.7 246 
F3 62±2.4 234 
F4 70±3.0 245 
F5 79±2.6 242 
F6 91±4.2 233 
F7 102±3.1 255 
 
From the values obtained it was observed that the weight variation was within the 
specified limits and the disintegration time was in the range of 224-255 sec. 
 
IN-VITRO DISSOLUTION STUDIES 
 In-vitro release study was performed for all the formulations for a period of 
10hours by using USP XXIV dissolution test apparatus Type I (basket apparatus). The 
data obtained was used to calculate the percentage cumulative release and plots were 
drawn by taking time vs. percentage cumulative release.  
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Table 12: In-vitro drug release of Losartan pharmacosomes 
 
 
 
 
    Fig. 4 In-vitro comparative diffusion profile of pharmacosomes containing losartan 
 
 
Time 
(hrs) Pure Drug 
% Cumulative Release 
F1 F2 F3 F4 F5 F6 F7 
0.25 2.51 4.60 3.29 2.83 2.85 3.07 3.95 3.07 
0.5 8.66 11.58 10.37 9.88 8.64 9.54 7.85 6.19 
1 12.33 21.29 18.07 16.94 14.21 15.73 14.26 13.42 
2 19.27 33.16 27.68 25.65 20.14 23.46 23.02 18.85 
3 28.21 40.64 38.42 34.49 33.24 41.51 29.51 21.52 
4 37.10 53.21 46.63 42.92 40.23 47.43 41.46 32.94 
5 43.54 58.55 53.17 48.19 45.75 50.85 49.00 45.18 
6 50.98 65.77 59.40 52.08 46.98 52.30 50.76 53.62 
7 55.88 73.50 64.81 57.30 51.27 56.74 53.95 54.05 
8 57.62 84.16 71.54 62.69 60.20 62.25 63.16 59.54 
9 58.27 90.19 82.79 71.20 74.48 74.25 72.60 73.60 
10 60.42 94.69 90.05 85.07 83.05 84.44 83.34 79.49 
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The pharmacosomes of Losartan showed better dissolution profile than the pure 
drug. Unlike the free Losartan (which showed a total of only 60.42% drug release at the 
end of the 10 hour), all the formulation showed the percentage cumulative drug release in 
the range of 79.49 – 94.69%. The formulation F1 with drug: soya lecithin ratio of 1:1 
showed the maximum release of 94.69% at the10th hour. The solid dispersion is a complex 
process which is affected by various factors like the particle size, crystal habit, surface 
area, surface energies and wettability. Wetting and dispersion properties of phospholipids 
(an amphiphilic surfactant) increased the solubility of the drug and hence improved the 
dissolution profile of the complex.  
 
X-RAY POWDER DIFFRACTION (XRD) ANALYSIS 
  
The XRD pattern of the pure drug (Losartan), soya lecithin and the selected 
formulation (F1) are shown in Fig: 5. Fig: 6 and Fig: 7. Characteristic diffraction peaks 
were observed for Losartan. On the other hand, the formulation F1 was characterized by 
less intensity of the diffraction peak when compared to that of the pure drug. This clearly 
indicates the reduction in the crystallinity of Losartan in pharmacosomes.  
 
 
 
 
 
 
              
                  Fig 5: XRD pattern of pure drug (Losartan) 
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Fig 6: XRD pattern of soya lecithin 
 
 
 
 
 
 
 
 
 
 
Fig 7: XRD pattern of Losartan pharmacosomes (F1) 
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SCANNING ELECTRON MICROSCOPY (SEM) ANALYSIS 
 
Particle morphology was determined by scanning electron microscopy. The SEM 
image showed that the pharmacosomes were disc shaped. 
 
 
 
 
Fig 8: SME image of Losartan pharmacosomes (F1) 
 
 
 
 
RELEASE KINETIC ANALYSIS 
 
Based on the data obtained from the in-vitro drug release studies the best 
formulation F1 was analyzed for the release kinetic studies. The cumulative release of drug 
was fitted into various plots like Zero order, First order and Higuchi model to know the 
pattern of release and Korsmeyer - pappas model in order to find out the mechanism of 
release from the prepared pharmacosomes. The model that best fits the release data is 
selected based on the regression coefficient value of various models.  
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Fig 9: Zero order plot of F1 
 
 
 
Fig 10: First order plot of F1 
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Fig 11: Higuchi plot of F1 
 
 
Fig 12: Korsmeyer-Peppas model of F1 
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Table 13: Result of kinetic analysis 
 
 
 
Formulation 
Zero 
order 
First 
order 
Higuchi 
model 
Korsmeyer- 
Peppas model 
 
R2 
 
R2 
 
R2 
 
N 
 
R2 
 
F1 
 
0.9801 
 
0.9172 
 
0.7602 
 
0.7641 
 
0.9835 
 
 
 
 From the regression coefficient values obtained, it was found out that the 
formulation follows the near Zero order kinetics. The slope value (n) obtained from 
peppas plot was 0.7641, which indicates that the formulation followed non- Fickian 
diffusion mechanism of drug release. 
 
STABILITY STUDIES 
 
Stability studies of best formulation (F1) was carried out at an accelerated temperature of 
40± 2°C and a relative humidity of  70 %± 5% RH in humidity control oven for 45 days. 
After 45 days the sample was evaluated for the physical appearance, drug content, and in-
vitro drug release studies. The values are as shown in the table. 
 
Table 14: Stability studies of F1 formulation 
 
 
Sl. no 
 
Accelerated temperature of 40± 2°C/RH 70 ± 5% 
 
  Parameters 
 
 
Initial 
 
30th day 
 
45th day 
1 Physical 
appearance 
 
Light  
 
Yellow 
Light  
 
Yellow 
Light  
 
Yellow 
2 Drug content 
 
 
96.83 
 
95.90 
 
94.97 
3 % 
Cumulative 
release at 
10th hr 
 
94.69 
 
93.78 
 
93.54 
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 After the study for 45 days it was concluded that there was no major changes in the 
various parameters evaluated like physical appearance, percentage drug content and in-
vitro drug dissolution study of F1 at 40± 2°C. Thus, it can be conducted that, F1 is stable at 
a temperature of 40± 2°C and at a relative humidity of 70± 5% for a period of 45 days. 
Summary 
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SUMMARY 
Losartan is an angiotension II receptor antagonist drug used mainly to treat high 
blood pressure. It is well absorbed oral administration and undergoes significant first-pass 
metabolism. It may also delay progression of diabetic nephropathy and is associated with a 
positive clinical outcome in that regard. Lowering high blood pressure helps prevent 
strokes, heart attacks, and kidney problems. It works by relaxing blood vessels so the 
blood can flow more easily. It is freely soluble in water and sparingly soluble in ethyl 
acetate, butyl acetate and cyclohexane, and the solubility in these three solvents varys little 
with the temperature, which affect it’s dissolution in GI fluid and leads to poor 
bioavailability. 
Hence the present study was aimed to develop a newer dosage form, the 
pharmacosomes, in order to avoid drug loss and to improve the bioavailability of the drug. 
Formulation 
 Losartan pharmacosomes was prepared by the solvent evaporation technique using 
different ratios of drug and soya lecithin. The prepared pharmacosomes were filled into 
capsules, a total of 7 formulations were prepared. 
Evaluation   
Compatibility studies showed that the drug and the excipient are compatible with 
each other. The pharmacosomes were subjected to various preformulation and post 
formulation studies. All the parameters obtained were within the limits. 
The angle of repose for all the formulations showed good flow character and all the 
results were within the prescribed limits. The drug content of Losartan in the complexes 
was found to be in the range 88.60% - 96.83% w/w indicating the presences of an 
acceptable amount of drug in the formulations. The formulation F1 (drug: lecithin ratio of 
1:1) showed the maximum drug content of 96.84% w/w 
The solubility studies revealed that the solubility of the Losartan pharmacosomes 
was much higher than the pure drug. The formulation F1 exhibited the highest degree of 
solubility. 
Summary 
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The drug release profile suggested that at the end of the 10 hour study, all 
formulation showed the percentage cumulative drug release in the range of 79.49% - 
94.69%. The formulation F1 showed the maximum release of 94.69% at the 10th hour. 
Based on all the above evaluation studies, it was observed that the best formulation was F1 
with a drug: lecithin ratio of 1:1. 
The X-ray powder diffraction analysis, scanning electron microscopy, release 
kinetics and stability studies were conducted for the optimized formulation F1. The XRD 
studies confirmed the formulation of the complex. The pharmacosomes were found to be 
disc shaped in scanning electron microscopy. The release kinetic analysis indicated that 
the F1 formulation follows the near Zero order release kinetics and non-Fickian diffusion 
mechanism of drug release. The formulation was stored in the stability chamber to 
ascertain the effect of extreme temperature variations on physical consistency and the drug 
content of the pharmacosome. The results of the stability study suggested that there was no 
significant alteration in the drug content of the pharmacosome. 
 On the basis of all the evaluation studies it was observed that the best formulation 
was F1 with a drug: lecithin ratio of 1:1.   
Conclusion 
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CONCLUSION 
In the present study the Losartan- phospholipid complexes (pharmacosomes) were 
prepared by a simple and reproducible method. The physicochemical investigations 
confirmed that Losartan formed a complex with phospholipids with better solubility and 
dissolution profile. The phospholipid complex of Losartan may be of potential use for 
improving bioavailability. As the phospholipid complex have also been reported to reduce 
the GI toxicity of the drugs, the phospholipid complex of Losartan may also be useful or 
minimizing the GI toxicity of Losartan. The pharmacosomes may be developed for other 
drugs with poor bioavailability and GI side effects. Thus, the formulated pharmacosomes 
seem to be potential candidate as an oral controlled drug delivery system in this era of 
novel and controlled drug delivery systems. The developed formulations are expected to 
improve the patient compliance and from better dosage regimen  
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